The expansion stage seeks to establish the overall response rate (ORR), duration of response (DR) and safety of five patient cohorts

Basel, Switzerland (ots/PRNewswire) - Mundipharma EDO GmbH, part
of the Mundipharma global network of independent associated
companies, today announced that the first patient has been enrolled
in the expansion stage of a Phase I/II clinical trial of
tinostamustine in patients with relapsed/refractory (R/R)
haematological malignancies in the US and Europe which they are
conducting in conjunction with Imbrium Therapeutics L.P., an
operating subsidiary of Purdue Pharma L.P.

Following the successful completion of the dose-escalation phase
to determine the safety, tolerability and recommended Phase II dose,
the expansion stage seeks to establish the ORR, DR and safety of five
cohorts of patients with R/R cancer, specifically: multiple myeloma
(MM), Hodgkin lymphoma (HL), peripheral T-cell lymphoma (PTCL),
cutaneous T-cell lymphoma (CTCL) and T-cell prolymphocytic leukaemia
(T-PLL). Each study arm will run separately, with results announced
as they become available.1

Tinostamustine is an alkylating deacetylase inhibiting molecule
that, in preclinical studies, has been shown to improve drug access
to the DNA strands within cancer cells, break them and counteract
damage repair.2-4 Preclinical studies suggest that these
complementary and simultaneous modes of action have the potential to
overcome resistance.4,5

Lead study investigator Dr Owen O'Connor, Columbia University
Medical Center, commented: "Initial results in the dose-escalation
phase of the study have been promising and our aim now is to
establish the efficacy and safety of the treatment in cancer types
for patients with very limited treatment options, either because
their cancer is rare or is not responding to other treatments."

Dr Thomas Mehrling, CEO of Mundipharma EDO added: "This is an
important milestone for both Mundipharma EDO and tinostamustine. Our
focus as a company is on areas where we can bring benefit to cancer
patients with significant unmet need and we, in conjunction with
Imbrium Therapeutics, are excited to progress this compound."

1. clinicaltrials.gov/ct2/show/NCT02576496
2. Lo?pez-Iglesias. Blood 2014;124:(21)
3. Lo?pez-Iglesias. 15th International Myeloma Workshop. 2015. Rome,
Italy
4. Di Filippi, et al. ASH. 6 December 2015
5. Yan, et al. Cancer Research 2012;72(Suppl 1):Abstract 2741

ots Originaltext: Mundipharma EDO
Im Internet recherchierbar: http://www.presseportal.de

Contact:
https://www.edoncology.com/latest-news/
References:
Contact:
Tiffany Fretwell
Tiffany.fretwell@mundipharma.com
+44-(0)-1223-393-361
Helen Rae
helenrae@makarahealth.com
+44-(0)-23-81-247-327

Original-Content von: Mundipharma EDO, übermittelt durch news aktuell